Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5357960 | 0.83 | KDM4E (0.48) | ALDH1A1KDM4EPOLBFUCA1MAPT | |
| SCHEMBL12472582 | 0.81 | ALDH1A1 (0.41) | ALDH1A1KDM4EPOLBFUCA1MAPT | |
| SCHEMBL12472580 | 0.81 | ALDH1A1 (0.41) | ALDH1A1KDM4EPOLBFUCA1MAPT | |
| SCHEMBL21787787 | 0.81 | ALDH1A1 (0.47) | ALDH1A1KDM4EPOLBMAPTLMNA | |
| SCHEMBL3907975 | 0.79 | TTR (0.58) | ALDH1A1KDM4EPOLBMAPTL3MBTL1 | |
| SCHEMBL22890574 | 0.78 | ALDH1A1 (0.39) | ALDH1A1KDM4EPOLBFUCA1MAPT | |
| SCHEMBL3179093 | 0.77 | MAPT (0.61) | ALDH1A1KDM4EPOLBFUCA1MAPT | |
| SCHEMBL29072286 | 0.76 | ALDH1A1 (0.42) | ALDH1A1KDM4EPOLBMAPTL3MBTL1 | |
| SCHEMBL12087063 | 0.75 | KDM4E (0.40) | ALDH1A1KDM4EPOLBMAPTL3MBTL1 | |
| SCHEMBL20805350 | 0.75 | MAPT (0.44) | ALDH1A1KDM4EMAPTL3MBTL1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184642-A | Aromatic ring system heterocycle compound, and pharmaceutical composition and application thereof | 中国药科大学 | 2024-06-14 | — | — | CN | disclosed |
| US-20230077268-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. | 2023-03-09 | — | — | US | disclosed |
| US-11427558-B1 | Indazoles and azaindazoles as LRRK2 inhibitors | ESCAPE Bio, Inc. (US) | 2022-08-30 | — | — | US | disclosed |
| EP-3997081-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | Escape Bio, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-114450274-A | Indazoles and azaindazoles as LRRK2 inhibitors | 伊斯凯普生物公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-106946848-B | Derivatives of 1-phenyl-2-pyridylalkylalcohols as phosphodiesterase inhibitors | 奇斯药制品公司 | 2022-01-04 | — | — | CN | disclosed |
| WO-2021007477-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2021-01-14 | — | — | WO | disclosed |
| WO-2021007477-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2021-01-14 | — | — | WO | disclosed |
| US-9931327-B2 | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-04-03 | — | — | US | disclosed |
| US-9931327-B2 | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-04-03 | — | — | US | disclosed |
| WO-2010020556-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
| US-20090306079-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION | 2009-12-10 | — | — | US | disclosed |
| US-20090306079-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION | 2009-12-10 | — | — | US | disclosed |
| EP-1694659-B1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | SCHERING CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. | 2008-04-17 | — | — | US | disclosed |
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. | 2008-04-17 | — | — | US | disclosed |
| US-20070264230-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION | 2007-11-15 | — | — | US | disclosed |
| US-20070264230-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION | 2007-11-15 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | CCR2, ACKR3, CX3CR1 | ALDH1A1 500/4885KDM4E 4758/4885POLB 3944/4885 |
| US-11427558-B1 | Indazoles and azaindazoles as LRRK2 inhibitors | LRRK2, PARK7, GDI2 | ALDH1A1 1904/4885KDM4E 1401/4885POLB 4324/4885 |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, ACKR3, CXCR1 | ALDH1A1 1019/4885KDM4E 4760/4885POLB 2094/4885 |
| US-20070264230-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | CXCR1, CCR2, CX3CR1 | ALDH1A1 348/4885KDM4E 4781/4885POLB 3557/4885 |
| US-20230077268-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, GDI2 | ALDH1A1 1904/4885KDM4E 1401/4885POLB 4324/4885 |
| US-20090306079-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | CCR1, ACKR3, CXCR1 | ALDH1A1 1019/4885KDM4E 4760/4885POLB 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.